C-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study
Advances in Clinical and Experimental Medicine · 21.03.2024 · 33 (7) · 691-698
DOI: 10.17219/acem/185254 ↗Kurz gefasst
Fall-Kontroll-Studie in der Zeitschrift Advances in Clinical and Experimental Medicine, online erschienen am 21.03.2024. Verfasst von Mehmet Ali Gul und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Faculty of Medicine, Amasya University, Turkey. Hauptthemen laut MEDLINE: COVID-19, Biomarkers, Collagen Type I, C-Reactive Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Coronavirus disease 19 (COVID-19) is a viral infection mediated by coronavirus-2 that causes severe acute respiratory syndrome (SARS-CoV-2). The disease may affect biochemical parameters and electrolytes. C-terminal cross-linking telopeptide (CTX-I) is released during mature bone resorption and is a biomarker for predicting bone resorption. OBJECTIVES: As the pandemic progressed, understanding the effects of COVID-19 disease remained critical. Inflammatory responses triggered by the virus can result in a bone metabolism regulation imbalance. As such, this study aimed to analyze serum levels of CTX-I, calcium (CA), phosphorus (P), magnesium (Mg), C-reactive protein (CRP), and alkaline phosphatase (ALP) in COVID-19 patients to investigate the relationship between bone resorption and the disease. MATERIAL AND METHODS: The study included 56 individuals with COVID-19 (divided into mild, moderate and severe subgroups depending on disease severity) and 25 healthy adults as a control group. Serum CTX-I concentrations were measured with enzyme-linked immunosorbent assay (ELISA). In addition, CRP, Ca, Mg, P, and ALP levels were measured using an automated clinical chemistry analyzer. RESULTS: Serum CTX-I levels were significantly higher in COVID-19 patients than in the control group (p < 0.05). Furthermore, a positive weak relationship was detected between CRP and CTX-I (r = 0.303, p < 0.05). CONCLUSIONS: Increased serum CTX-I levels in the patient group caused COVID-19-driven bone degradation, though serum CTX-I levels did not differ according to disease severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biochemistry, Faculty of Medicine, Amasya University, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Turkey.
- Department of Nutrition and Dietetics, Faculty of Healthy Sciences, Ataturk University, Erzurum, Turkey.
- Department of Medical Biochemistry, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
- Department of Chemical Technology, Erzurum Vocational Training College, Ataturk University, Turkey.
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Zitieren
APA
Gul, M. A., Kurt, N., Ozgeris, F. B., Yuce, N., Kocak, O. F., & Parlak, E. (2024). C-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study. Advances in Clinical and Experimental Medicine, 33(7), 691-698. https://doi.org/10.17219/acem/185254
Vancouver
Gul MA, Kurt N, Ozgeris FB, Yuce N, Kocak OF, Parlak E. C-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study. Advances in Clinical and Experimental Medicine. 2024;33(7):691-698. doi:10.17219/acem/185254
BibTeX
@article{Gul2024,
author = {Gul, Mehmet Ali and Kurt, Nezahat and Ozgeris, Fatma Betul and Yuce, Neslihan and Kocak, Omer Faruk and Parlak, Emine},
title = {C-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study},
journal = {Advances in Clinical and Experimental Medicine},
year = {2024},
volume = {33},
number = {7},
pages = {691--698},
doi = {10.17219/acem/185254}
}
EUVIMED